健民集团(600976) - 2021 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders increased by 272.49% to CNY 70,434,076.46 compared to the same period last year[11]. - Operating income rose by 91.06% to CNY 841,378,502.19 compared to the same period last year[9]. - Basic earnings per share increased by 283.33% to CNY 0.46 compared to the same period last year[9]. - The company reported a significant increase in sales revenue, with cash received from sales reaching CNY 684,257,838.20 in Q1 2021, up from CNY 432,840,758.19 in Q1 2020, representing a growth of approximately 58%[48]. - Net profit for Q1 2021 reached CNY 53,792,494.34, up 246.5% from CNY 15,518,574.73 in the same period last year[43]. - The total comprehensive income for Q1 2021 was CNY 53,792,494.34, compared to CNY 15,518,574.73 in Q1 2020, marking a growth of 246.5%[44]. Cash Flow - Net cash flow from operating activities increased by 481.57% to CNY 39,228,687.71 compared to the same period last year[9]. - In Q1 2021, the cash inflow from operating activities was CNY 713,106,891.34, a significant increase from CNY 439,803,206.59 in Q1 2020, representing a growth of approximately 62.2%[48]. - The net cash flow from operating activities for Q1 2021 was CNY 39,228,687.71, compared to a negative cash flow of CNY -10,280,908.25 in Q1 2020, indicating a turnaround in performance[48]. - The total cash inflow from investment activities in Q1 2021 was CNY 459,025,978.35, up from CNY 203,774,258.79 in Q1 2020, marking an increase of about 125.5%[49]. - The net cash flow from investment activities for Q1 2021 was CNY 32,635,513.05, a recovery from a negative cash flow of CNY -16,256,165.94 in Q1 2020[49]. Assets and Liabilities - Total assets increased by 6.06% to CNY 2,563,552,582.41 compared to the end of the previous year[9]. - The total liabilities increased by 24.23% to RMB 571,661,463.81, primarily due to increased marketing expenses related to higher sales[20]. - The company's total assets amounted to approximately CNY 2.56 billion, an increase from CNY 2.42 billion at the end of 2020, representing a growth of about 6%[30]. - The total liabilities of the company increased to CNY 1.21 billion from CNY 1.09 billion, marking an increase of about 11%[30]. Shareholder Information - The total number of shareholders at the end of the reporting period was 8,997[14]. - The largest shareholder, Huali Pharmaceutical Group Co., Ltd., holds 25.09% of the shares[14]. - The company repurchased a total of 1,432,001 shares, accounting for 0.93% of the total share capital, at an average price of RMB 27.93 per share, totaling RMB 39,992,706.26[22]. - The company plans to utilize the repurchased shares within 36 months; otherwise, it will cancel the unused shares as per legal requirements[23]. Research and Development - Research and development expenses rose by 85.30% to RMB 8,243,887.67, reflecting increased investment in R&D activities[20]. - Research and development expenses for Q1 2021 were ¥8,243,887.67, up from ¥4,448,948.50 in Q1 2020, reflecting an increase of 85.5%[40]. Tax and Expenses - The company experienced a 140.19% increase in income tax expenses, amounting to RMB 7,424,556.89, due to profit growth[20]. - The tax expenses for Q1 2021 were CNY 4,249,851.11, compared to CNY 2,156,219.07 in Q1 2020, indicating higher profitability[43].